TY - JOUR
T1 - Imaging advances in the management of kidney cancer
AU - Krajewski, Katherine M.
AU - Pedrosa, Ivan
N1 - Funding Information:
Supported by National Cancer Institute grants U01 CA207091 (to I.P.), P50CA196516 (to I.P.), and R01CA154475 (to I.P.).
Publisher Copyright:
© 2018 by American Society of Clinical Oncology
PY - 2018/12/20
Y1 - 2018/12/20
N2 - New developments in cross-sectional imaging, including contrast-enhanced ultrasound, dual-energy computed tomography, multiparametric magnetic resonance imaging, single-photon emission computed tomography, and positron emission tomography, together with novel application of existing and novel radiotracers, have changed the landscape of renal mass characterization (ie, virtual biopsy) as well as the detection of metastatic disease, prognostication, and response assessment in patients with advanced kidney cancer. A host of imaging response criteria have been developed to characterize the response to targeted and immune therapies and correlate with patient outcomes, each with strengths and limitations. Recent efforts to advance the field are aimed at increasing objectivity with quantitative techniques and the use of banks of imaging data to match the vast genomic data that are becoming available. The emerging field of radiogenomics has the potential to transform further the role of imaging in kidney cancer management through eventual noninvasive characterization of the tumor histology and genetic microenvironment in single renal masses and/or metastatic disease. We review of the effect of currently available imaging techniques in the management of patients with kidney cancer, including localized, locally advanced, and metastatic disease.
AB - New developments in cross-sectional imaging, including contrast-enhanced ultrasound, dual-energy computed tomography, multiparametric magnetic resonance imaging, single-photon emission computed tomography, and positron emission tomography, together with novel application of existing and novel radiotracers, have changed the landscape of renal mass characterization (ie, virtual biopsy) as well as the detection of metastatic disease, prognostication, and response assessment in patients with advanced kidney cancer. A host of imaging response criteria have been developed to characterize the response to targeted and immune therapies and correlate with patient outcomes, each with strengths and limitations. Recent efforts to advance the field are aimed at increasing objectivity with quantitative techniques and the use of banks of imaging data to match the vast genomic data that are becoming available. The emerging field of radiogenomics has the potential to transform further the role of imaging in kidney cancer management through eventual noninvasive characterization of the tumor histology and genetic microenvironment in single renal masses and/or metastatic disease. We review of the effect of currently available imaging techniques in the management of patients with kidney cancer, including localized, locally advanced, and metastatic disease.
UR - http://www.scopus.com/inward/record.url?scp=85058566384&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058566384&partnerID=8YFLogxK
U2 - 10.1200/JCO.2018.79.1236
DO - 10.1200/JCO.2018.79.1236
M3 - Review article
C2 - 30372386
AN - SCOPUS:85058566384
SN - 0732-183X
VL - 36
SP - 3582
EP - 3590
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 36
ER -